Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy CRBP?
Source: NASDAQ.COM
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRBP
Wall Street analysts forecast CRBP stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.590
Low
38.00
Averages
46.71
High
53.00
Current: 10.590
Low
38.00
Averages
46.71
High
53.00
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Corbus Aligns with FDA on CRB-701 Registration Pathway
- FDA Registration Alignment: Corbus Pharmaceuticals has broadly aligned with the FDA on the registration pathway for CRB-701, enabling the company to advance the proposed study design for head and neck squamous cell carcinoma and cervical cancer, potentially accelerating the drug's approval process.
- Study Design Details: The registrational study for CRB-701 will include a randomized controlled trial comparing its efficacy and safety against physician's choice chemotherapy, with objective response rate (ORR) as the primary endpoint, and potential full approval based on overall survival (OS) benefits.
- Study Initiation Timeline: The registrational study for second-line HNSCC is expected to begin in mid-2026, while a phase 1/2 study of CRB-701 in both HNSCC and cervical cancer is ongoing, with updated data to be presented at the 2026 American Society of Clinical Oncology Annual Meeting.
- Executive Change: The company's Chief Medical Officer, Dominic Smethurst, will step down on June 30, 2026, which may impact the company's strategic direction and clinical research timelines.
See More
FDA Approves Corbus' Registrational Study Design
- Positive FDA Feedback: Corbus has achieved broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, which is expected to facilitate accelerated approval and address unmet medical needs, enhancing the company's competitive position in the market.
- Clinical Data Update: Updated monotherapy data for CRB-701 will be presented at the 2026 ASCO Annual Meeting, including clinical response durability and patient subgroup analysis, further validating its efficacy and boosting investor confidence.
- Executive Transition: Chief Medical Officer Dominic Smethurst will step down on June 30, 2026, and the company will welcome new senior leaders to better support the late-stage development of CRB-701, ensuring success during this critical phase.
- Future Outlook: Corbus plans to initiate the registrational study for CRB-701 in mid-2026 and anticipates reporting data on its combination with Keytruda in Q4 2026, further advancing the potential for registration-enabling trials.
See More
Corbus Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Highlights: Corbus Pharmaceuticals reported a Q4 2025 GAAP EPS of -$1.25, beating expectations by $0.40, indicating some improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company had $163.3 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for ongoing projects.
- Capital Raising: In Q4 2025, Corbus completed a public offering that raised $75 million in gross proceeds, providing crucial funding for future R&D and operational needs, thereby enhancing its competitive position in the market.
- Market Outlook: Despite a decline in early-stage results for the obesity drug CRB-913, the approaching summer 2026 obesity data catalyst keeps market sentiment cautiously optimistic, reflecting investor expectations for potential growth opportunities.
See More
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
See More
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Corbus Aligns with FDA on CRB-701 Registration Pathway
- FDA Registration Alignment: Corbus Pharmaceuticals has broadly aligned with the FDA on the registration pathway for CRB-701, enabling the company to advance the proposed study design for head and neck squamous cell carcinoma and cervical cancer, potentially accelerating the drug's approval process.
- Study Design Details: The registrational study for CRB-701 will include a randomized controlled trial comparing its efficacy and safety against physician's choice chemotherapy, with objective response rate (ORR) as the primary endpoint, and potential full approval based on overall survival (OS) benefits.
- Study Initiation Timeline: The registrational study for second-line HNSCC is expected to begin in mid-2026, while a phase 1/2 study of CRB-701 in both HNSCC and cervical cancer is ongoing, with updated data to be presented at the 2026 American Society of Clinical Oncology Annual Meeting.
- Executive Change: The company's Chief Medical Officer, Dominic Smethurst, will step down on June 30, 2026, which may impact the company's strategic direction and clinical research timelines.
See More
FDA Approves Corbus' Registrational Study Design
- Positive FDA Feedback: Corbus has achieved broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, which is expected to facilitate accelerated approval and address unmet medical needs, enhancing the company's competitive position in the market.
- Clinical Data Update: Updated monotherapy data for CRB-701 will be presented at the 2026 ASCO Annual Meeting, including clinical response durability and patient subgroup analysis, further validating its efficacy and boosting investor confidence.
- Executive Transition: Chief Medical Officer Dominic Smethurst will step down on June 30, 2026, and the company will welcome new senior leaders to better support the late-stage development of CRB-701, ensuring success during this critical phase.
- Future Outlook: Corbus plans to initiate the registrational study for CRB-701 in mid-2026 and anticipates reporting data on its combination with Keytruda in Q4 2026, further advancing the potential for registration-enabling trials.
See More
Corbus Pharmaceuticals Reports Q4 2025 Financial Results
- Financial Highlights: Corbus Pharmaceuticals reported a Q4 2025 GAAP EPS of -$1.25, beating expectations by $0.40, indicating some improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company had $163.3 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028, demonstrating a solid financial buffer for ongoing projects.
- Capital Raising: In Q4 2025, Corbus completed a public offering that raised $75 million in gross proceeds, providing crucial funding for future R&D and operational needs, thereby enhancing its competitive position in the market.
- Market Outlook: Despite a decline in early-stage results for the obesity drug CRB-913, the approaching summer 2026 obesity data catalyst keeps market sentiment cautiously optimistic, reflecting investor expectations for potential growth opportunities.
See More
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
- CRB-701 Clinical Data: At the 2025 ESMO, Corbus presented promising efficacy data for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with an unconfirmed objective response rate of 47.6% in HNSCC, highlighting its potential in treating challenging tumors.
- CRB-913 Weight Loss Results: In the 14-day SAD/MAD study of CRB-913, patients experienced a 2.9% weight loss with favorable GI safety, suggesting it could serve as a novel long-term management solution for chronic obesity patients.
- Funding Update: Corbus completed a $75 million public offering in Q4 2025, extending its cash runway into 2028, thereby enhancing financial stability to support future clinical development.
- Financial Performance: For Q4 2025, Corbus reported a net loss of approximately $20.6 million, significantly up from $9.5 million in Q4 2024, primarily due to increased clinical development expenses, indicating ongoing investment in R&D.
See More
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
See More
